Myonexus Therapeutics, Inc. Email Format
Pharmaceutical ManufacturingOhio, United States2-10 Employees
Myonexus Therapeutics, Inc. is a clinical-stage pharmaceutical manufacturing company based in Columbus, Ohio, United States. It focuses on developing rare-disease gene therapies for limb-girdle muscular dystrophy (LGMD) and aims to deliver corrective treatments for LGMD types 2E, 2D, 2B, 2C, and 2L. The company pursued five LGMD gene therapy candidates with Sarepta Therapeutics, three in clinical development and two in pre-clinical development, as of 2018-2019. In February 2019, Sarepta Therapeutics acquired Myonexus Therapeutics for $165 million. The organization employs between 2 and 10 people and reports revenue in the range of $0 to $1 million.